These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19029066)

  • 1. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
    Shaposhnik Z; Wang X; Trias J; Fraser H; Lusis AJ
    J Lipid Res; 2009 Apr; 50(4):623-9. PubMed ID: 19029066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.
    Fraser H; Hislop C; Christie RM; Rick HL; Reidy CA; Chouinard ML; Eacho PI; Gould KE; Trias J
    J Cardiovasc Pharmacol; 2009 Jan; 53(1):60-5. PubMed ID: 19129734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
    van der Hoorn JW; Kleemann R; Havekes LM; Kooistra T; Princen HM; Jukema JW
    J Hypertens; 2007 Dec; 25(12):2454-62. PubMed ID: 17984667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice.
    Park KY; Heo TH
    Cardiovasc Ther; 2018 Dec; 36(6):e12476. PubMed ID: 30378752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-atherosclerotic effects of pravastatin in brachiocephalic artery in comparison with en face aorta and aortic roots in ApoE/LDLR
    Kostogrys RB; Franczyk-Zarow M; Gasior-Glogowska M; Kus E; Jasztal A; Wrobel TP; Baranska M; Czyzynska-Cichon I; Drahun A; Manterys A; Chlopicki S
    Pharmacol Rep; 2017 Feb; 69(1):112-118. PubMed ID: 27915184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
    Rosenson RS; Elliott M; Stasiv Y; Hislop C;
    Eur Heart J; 2011 Apr; 32(8):999-1005. PubMed ID: 21081550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice.
    Zhou XX; Gao PJ; Sun BG
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):373-9. PubMed ID: 19018808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
    Leitinger N; Watson AD; Hama SY; Ivandic B; Qiao JH; Huber J; Faull KF; Grass DS; Navab M; Fogelman AM; de Beer FC; Lusis AJ; Berliner JA
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1291-8. PubMed ID: 10323782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.
    De Luca D; Minucci A; Piastra M; Cogo PE; Vendittelli F; Marzano L; Gentile L; Giardina B; Conti G; Capoluongo ED
    PLoS One; 2012; 7(10):e47066. PubMed ID: 23071714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
    Woo JM; Lin Z; Navab M; Van Dyck C; Trejo-Lopez Y; Woo KM; Li H; Castellani LW; Wang X; Iikuni N; Rullo OJ; Wu H; La Cava A; Fogelman AM; Lusis AJ; Tsao BP
    Arthritis Res Ther; 2010; 12(3):R93. PubMed ID: 20482780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin polarizes the phenotype of macrophages toward M2 and elevates serum cholesterol levels in apolipoprotein E knockout mice.
    Zhang X; Xiao S; Li Q
    J Int Med Res; 2018 Aug; 46(8):3365-3373. PubMed ID: 30058421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice.
    She ZG; Zheng W; Wei YS; Chen HZ; Wang AB; Li HL; Liu G; Zhang R; Liu JJ; Stallcup WB; Zhou Z; Liu DP; Liang CC
    Circ Res; 2009 May; 104(10):1160-8. PubMed ID: 19359600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.
    Park KY; Oh E; Kwak MK; Jun HS; Heo TH
    PLoS One; 2016; 11(3):e0150791. PubMed ID: 26950217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice.
    Song G; Tian H; Qin S; Sun X; Yao S; Zong C; Luo Y; Liu J; Yu Y; Sang H; Wang X
    Atherosclerosis; 2012 Mar; 221(1):55-65. PubMed ID: 22209213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of exogenous fibroblast growth factor 21 on atherosclerosis in apolipoprotein E deficient mice].
    Wu X; Lü Y; Fu K; Wang S; Zhao D; Peng H; Fan Q; Lü Y; Xin M; Liu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Feb; 42(2):126-31. PubMed ID: 24735623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment.
    Johnson J; Carson K; Williams H; Karanam S; Newby A; Angelini G; George S; Jackson C
    Circulation; 2005 Mar; 111(11):1422-30. PubMed ID: 15781753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
    Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
    J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice.
    Higashi Y; Sukhanov S; Shai SY; Danchuk S; Tang R; Snarski P; Li Z; Lobelle-Rich P; Wang M; Wang D; Yu H; Korthuis R; Delafontaine P
    Circulation; 2016 Jun; 133(23):2263-78. PubMed ID: 27154724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.
    Leite JO; Vaishnav U; Puglisi M; Fraser H; Trias J; Fernandez ML
    BMC Cardiovasc Disord; 2009 Feb; 9():7. PubMed ID: 19222850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.